Berhanu Kibret

Berhanu Kibret, PhD, is an Instructor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy. He is actively engaged in research related to the endocannabinoid system and its role in neuropsychiatric and neurodegenerative disorders, with a focus on CB2 receptors and their neuroimmune and behavioral implications.

Research Interests: Dr. Kibret's work explores the intricate mechanisms of the endocannabinoid system, particularly how neuronal and glial CB2 receptors modulate the effects of drugs of abuse, alcohol-induced behaviors, and dopamine dysregulation. His research bridges pharmacology, neuroscience, and immunology, with applications in addiction, mental health, and neurodegeneration.

The recent publications indicate a strong trend in studying CB2 receptor activation as a therapeutic strategy in CNS disorders, alcohol-related neuroimmune dysregulation, and wound healing. His work spans molecular pharmacology, behavioral testing in animal models, and clinical implications of cannabinoid use.

Scientific Awards:

• No awards explicitly mentioned in the provided text.

Advising and Grants: While no formal list of students or grants is provided, Dr. Kibret's active publication record and postdoctoral background suggest involvement in mentoring and research leadership. He has collaborated extensively with prominent researchers in cannabinoid pharmacology, indicating strong research network engagement.

Labs and Teams: Though not explicitly named, Dr. Kibret's research is likely conducted within a pharmacology or neuropharmacology laboratory at the University of Maryland School of Pharmacy, focusing on cannabinoid signaling, neurobehavior, and neuroimmunology. His past postdoctoral work at William Paterson University involved studies on CB2 receptors in neuropsychiatric models.